Cutler Group’s Immunocore IMCR Stock Holding History

Cutler Group’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,780	Closed	-$102K	–	3852
2023 Q1	$88K	Buy	+1,780	New	+$100K	0.01%	1038

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Cutler Group's IMCR Position: Q2 2023 in Review

Cutler Group sold out of Immunocore (IMCR) in Q2 2023, closing a stake of 1,780 shares — an estimated $102K sold.

Cutler Group first reported a position in IMCR in Q1 2023 and held it in 1 quarter. The position peaked at $88K in Q1 2023. 120 funds tracked by Wall St. Rank hold IMCR as of Q2 2023.

Cutler Group reported no remaining Immunocore position as of Q2 2023 after selling out during the quarter.
Cutler Group sold 1,780 Immunocore shares in Q2 2023, an estimated $102K.
Cutler Group first reported a position in Immunocore in Q1 2023 and held it in 1 quarter.
Cutler Group's Immunocore position peaked at $88K in Q1 2023.
120 funds tracked by Wall St. Rank held Immunocore as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.